Tag Archives: Andrew Fein

Analysts’ Top Healthcare Picks: Biogen (BIIB), Interpace Diagnostics Group (IDXG)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biogen (BIIB – Research Report), Interpace Diagnostics Group (IDXG – Research Report) and Cardiff Oncology (CRDF – Research Report) with bullish sentiments.

H.C. Wainwright Maintains Their Buy Rating on Pulmatrix (PULM)

In a report released yesterday, Andrew Fein from H.C. Wainwright maintained a Buy rating on Pulmatrix (PULM – Research Report), with a price target of $10.00. The company’s shares closed last Wednesday at $1.19. According to TipRanks.com, Fein is a

H.C. Wainwright Thinks AC Immune SA’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on AC Immune SA (ACIU – Research Report), with a price target of $11.00. The company’s shares closed last Wednesday at $4.80, close to its 52-week

Analysts Conflicted on These Healthcare Names: Strongbridge Biopharma (NASDAQ: SBBP) and Radius Health (NASDAQ: RDUS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Strongbridge Biopharma (SBBP – Research Report) and Radius Health (RDUS – Research Report). Strongbridge Biopharma (SBBP) H.C. Wainwright analyst Andrew Fein reiterated a Buy rating

Analysts Are Bullish on These Healthcare Stocks: BELLUS Health (BLU), Minerva Neurosciences (NERV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BELLUS Health (BLU – Research Report), Minerva Neurosciences (NERV – Research Report) and AVEO Pharma (AVEO – Research Report) with bullish sentiments.

H.C. Wainwright Thinks Acasti Pharma’s Stock is Going to Recover

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Acasti Pharma (ACST – Research Report), with a price target of $3.00. The company’s shares closed last Friday at $0.69, close to its 52-week low